704-P: Adults with Type 1 Diabetes Report Improved Quality of Life with the Omnipod 5 Automated Insulin Delivery System

Abstract

Type 1 diabetes (T1D) can lead to significant emotional distress and impaired quality of life (QoL). Hybrid closed-loop (HCL) technology seeks to relieve this burden, a goal with equal importance to improving glycemic outcomes. We evaluated change in QoL outcomes for adults (mean±SD, age 39±13y, T1D duration 19±12y, and baseline A1C 7.1±0.9%) before and after a 3-month outpatient study of HCL therapy with the Omnipod 5 System. Participants (N=115) completed validated assessment tools to capture various aspects of diabetes-related and generic QoL: the T1D Distress Survey (T1DDS), Hypoglycemic Confidence Scale (HCS), and World Health Organization Well-Being Index (WHO-5). Though QoL was relatively high at baseline across all 3 measures, we observed significant improvements in diabetes-related QoL with reduced T1DDS and increased HCS scores after 3 months of system use (Table). Among the T1DDS subscales, significant improvements were seen in powerlessness (change: ‑0.27), management distress (-0.18), hypoglycemia distress (-0.21), and eating distress (-0.24, all p<0.001). Generic QoL (WHO-5) was unchanged over the study period. In addition to glycemic efficacy and safety of the Omnipod 5 System (reported previously), these results reveal a significant improvement in QoL for adults with T1D and suggest features of the system may alleviate some of the burden associated with living with T1D.View largeDownload slideView largeDownload slide DisclosureC. J. Levy: Advisory Panel; Self; Dexcom, Inc., Eli Lilly and Company, Employee; Spouse/Partner; AbbVie Inc., Other Relationship; Self; Dexcom, Inc., Research Support; Self; Abbott Diabetes, Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care. W. H. Polonsky: Advisory Panel; Self; Intarcia Therapeutics, Inc., Consultant; Self; Abbott Diabetes, ADOCIA, Boehringer Ingelheim Pharmaceuticals, Inc., Dexcom, Inc., Insulet Corporation, Lilly Diabetes, Novo Nordisk, Onduo LLC., Sanofi US. K. K. Hood: Consultant; Self; Cecelia Health, Cercacor, LifeScan Diabetes Institute. S. A. Macleish: Advisory Panel; Self; Insulet Corporation. L. M. Huyett: Employee; Self; Insulet Corporation, Stock/Shareholder; Self; Insulet Corporation. T. Vienneau: Employee; Self; Insulet Corporation, Stock/Shareholder; Self; Insulet Corporation. T. T. Ly: Employee; Self; Insulet Corporation.FundingInsulet Corporation